GH1 and hypopituitarism: A development of new or worsening of pre-existing hypopituitarism occurred in 10 (19%) patients after a median follow-up of 36 months, requiring hormone replacement therapy with gonadal steroids and growth hormone in 7 patients, GH replacement in 2 patients, and thyroxine and hydrocortisone in 4 patients.